1World Health Organization.Definition,diagnosis and classification of diabetes mellitus and its cimplication.Part 1:Diagnosis and classifications of diabetes mellitus.In:Geneva;WHO Department of Non-communicable Diseases Survillance,1999.
2Unwin N,Shaw J,Zimmet P,et al.Impaired glucose tolerance and impaired fasting glycaemias:the current status on definition and intervention[J].Diabet Med,2002,19(9):708-723.
4Blake DR,Meigs JB,Muller DC,et al.Impaired glucose tolerance,but not impaired fasting glucose,is associated with increase levels of coronary heart disease rick factors:Results from the Baltimore Longitudinal Study on Aging[J].Diabetes,2004,53(9):2 095-2 100.
5American Diabetes Association and National Institute of Diabetes,Digestive and Kidney Disease.The prevention or delay of type 2 diabetes[J].Diabetes Care,2002,25(7):742-749.
1TriPathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance. Diabetes, 2000,49:975-980.
2The DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet, 1999,354:617-621.
3The DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med, 2001,161:397-405.
4Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care, 1999,22:920-924.
5Smits P. Thien T. Cardiovascular effects of suplphonylurea derivatives. Diabetologia 1995; 38:116 - 121.
6Leibowitz G. Cerasi E. Sulphonylurea treatment on NIDDM Patients with cardiovascular disease: a mixed blessing? Diabetologia 1996;39:503 - 514.
7Tumer R, Cull C, Holman R(UKPDS Group). UKPDS 17: a 9 year update of a randomized. controlled trial on the effect of improved metabolic control on complications in DIDDM. Ann Intern Med 1996; 124:136 - 145.
8Dubois M, Vantyghem MC, Schoonjans K, et al. Thiazolidnediones in type 2 diabetes. Role of peroxisome proliferator- activated recepotr gamma ( PPAR gamma). Ann Endocrinal(Paris) 2002; 63: 511- 523.
